Simcere Wins NMPA Nod to Start Clinical Trials for Novel EGFR/cMET Cancer Drug

Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potentialThe latest update is out from Simcere Pharmaceutical Group Limited ( (HK:2096) ). Simcere Pharmaceutical Group Limited has received approval from China’s National Medical Products Administration to begin clinical trials for SIM0610, an independently developed bispecific antibody-drug conjugate targeting EGFR and cMET in patients with locally advanced or metastatic solid tumors. SIM0610 is designed to induce tumor cell apoptosis via intracellular release of a topoisomerase I inhibitor and to address drug resistance mechanisms, particularly resistance to EGFR tyrosine kinase inhibitors; preclinical data have shown significant anti-tumor activity across multiple tumor models, underscoring Simcere’s push to strengthen its oncology pipeline and competitive position in targeted cancer therapies. The most recent analyst rating on (HK:2096) stock is a Buy with a HK$16.30 price target. To see the full list of analyst forecasts on Simcere Pharmaceutical Group Limited stock, see the HK:2096 Stock Forecast page. More about Simcere Pharmaceutical Group Limited Simcere Pharmaceutical Group Limited is an innovation- and R&D-driven pharmaceutical company that has established a State Key Laboratory of Neurology and Oncology Drug Development. It focuses on therapies in neuroscience, oncology, autoimmune diseases and anti-infective areas, and pursues forward-looking development in disease areas with significant future clinical needs, supported by in-house research and strategic partnerships with innovative companies and research institutes. Average Trading Volume: 8,403,511 Technical Sentiment Signal: Buy Current Market Cap: HK$34.03B